Ute Mercker

IBB Beteiligungsgesellschaft mbH (IBB Ventures) is the wholly-owned venture capital subsidiary of Investitionsbank Berlin. The firm was founded in 1997 to foster the development of regional businesses in selected areas and to strengthen the local labor market. The firm is headquartered in Berlin, Germany.

IBB Beteiligungsgesellschaft mbH (IBB Ventures) is the wholly-owned venture capital subsidiary of Investitionsbank Berlin. The firm was founded in 1997 to foster the development of regional businesses in selected areas and to strengthen the local labor market. The firm is headquartered in Berlin, Germany.

IBB Beteiligungsgesellschaft mbH (IBB Ventures) is the wholly-owned venture capital subsidiary of Investitionsbank Berlin. The firm was founded in 1997 to foster the development of regional businesses in selected areas and to strengthen the local labor market. The firm is headquartered in Berlin, Germany.

OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany.

OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany.

IBB Beteiligungsgesellschaft mbH (IBB Ventures) is the wholly-owned venture capital subsidiary of Investitionsbank Berlin. The firm was founded in 1997 to foster the development of regional businesses in selected areas and to strengthen the local labor market. The firm is headquartered in Berlin, Germany.

OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany.

OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany.

OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany.

OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany.

OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany.

IBB Beteiligungsgesellschaft mbH (IBB Ventures) is the wholly-owned venture capital subsidiary of Investitionsbank Berlin. The firm was founded in 1997 to foster the development of regional businesses in selected areas and to strengthen the local labor market. The firm is headquartered in Berlin, Germany.

OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany.

IBB Beteiligungsgesellschaft mbH (IBB Ventures) is the wholly-owned venture capital subsidiary of Investitionsbank Berlin. The firm was founded in 1997 to foster the development of regional businesses in selected areas and to strengthen the local labor market. The firm is headquartered in Berlin, Germany.

IBB Beteiligungsgesellschaft mbH (IBB Ventures) is the wholly-owned venture capital subsidiary of Investitionsbank Berlin. The firm was founded in 1997 to foster the development of regional businesses in selected areas and to strengthen the local labor market. The firm is headquartered in Berlin, Germany.

IBB Beteiligungsgesellschaft mbH (IBB Ventures) is the wholly-owned venture capital subsidiary of Investitionsbank Berlin. The firm was founded in 1997 to foster the development of regional businesses in selected areas and to strengthen the local labor market. The firm is headquartered in Berlin, Germany.

IBB Beteiligungsgesellschaft mbH (IBB Ventures) is the wholly-owned venture capital subsidiary of Investitionsbank Berlin. The firm was founded in 1997 to foster the development of regional businesses in selected areas and to strengthen the local labor market. The firm is headquartered in Berlin, Germany.

IBB Beteiligungsgesellschaft mbH (IBB Ventures) is the wholly-owned venture capital subsidiary of Investitionsbank Berlin. The firm was founded in 1997 to foster the development of regional businesses in selected areas and to strengthen the local labor market. The firm is headquartered in Berlin, Germany.

IBB Beteiligungsgesellschaft mbH (IBB Ventures) is the wholly-owned venture capital subsidiary of Investitionsbank Berlin. The firm was founded in 1997 to foster the development of regional businesses in selected areas and to strengthen the local labor market. The firm is headquartered in Berlin, Germany.

OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany.